Efficacy and safety of fingerroot-biosynthesized silver nanoparticles nasal spray for SARS-CoV-2 eradication in upper respiratory tract of the patients: A pilot study

Phase 1

• Conditions: Adults who had mild COVID-19 symptoms for no longer than 3 days and had the disease confirmed by real-time polymerase chain reaction (RT-PCR) or an antigen test; SARS-CoV-2; COVID-19; upper respiratory tract; fingerroot; silver nanoparticles

• Registration Number: TCTR20230817001
• Lead Sponsor: ational Research Council of Thailand (NRCT)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-08-17
• Last Update Posted: 19 August 2024
• Study Completion: 2024-12-21

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Age: at least 18 years old
2. COVID-19 was diagnosed by RT-PCR or an antigen test within 24 hours or within 3 days of the onset of symptoms
3. Mild COVID-19 symptoms
4. Willingness to take part in the current research
5. The SARS-CoV-2 RT-PCR cycle threshold is not more than 25

Exclusion Criteria

1. Allergy to silver or fingerroot
2. Pregnancy or lactation
3. Severe COVID-19 symptoms
4. Receiving antiviral treatment for COVID-19 before enrollment

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Viral culture 30 minutes after administration Cytopathic effect, Plaque titration

Secondary Outcome Measures

Name	Time	Method
Viral culture 4 hours after administration Cytopathic effect, Plaque titration,RT-PCR 30 minutes after administration Ct value,RT-PCR 4 hours after administration Ct value,Safety Administration, 30 minutes, 4 hours, 24 hours, 7 days after administration Adverse reactions,Silver level Baseline, 4 hours, 7 days after administration Blood and urine tests